source
- BioVie shares plunge as Parkinson’s trial results lack primary motor dataBioVie reported results of its Phase 2 SUNRISE-PD study in early‑stage Parkinson’s disease. The double‑blind, placebo‑controlled trial enrolled 57 patients who had not yet received carbidopa/levodo…
- Sarepta delays Elevidys study readout while Emergent cuts 90 jobsSarepta Therapeutics told investors that the readout for its non‑ambulatory Elevidys trial will not be available by the end of the year as previously expected. The company indicated the delay durin…